+

WO2009023164A3 - Induction de l'immunité des muqueuses - Google Patents

Induction de l'immunité des muqueuses Download PDF

Info

Publication number
WO2009023164A3
WO2009023164A3 PCT/US2008/009584 US2008009584W WO2009023164A3 WO 2009023164 A3 WO2009023164 A3 WO 2009023164A3 US 2008009584 W US2008009584 W US 2008009584W WO 2009023164 A3 WO2009023164 A3 WO 2009023164A3
Authority
WO
WIPO (PCT)
Prior art keywords
mucosal immunity
induction
inducing
cell
methods
Prior art date
Application number
PCT/US2008/009584
Other languages
English (en)
Other versions
WO2009023164A2 (fr
Inventor
Marc Lipsitch
Richard Malley
Krzysztof Trzcinski
Original Assignee
Harvard College
Childrens Hospital Boston
Marc Lipsitch
Richard Malley
Krzysztof Trzcinski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College, Childrens Hospital Boston, Marc Lipsitch, Richard Malley, Krzysztof Trzcinski filed Critical Harvard College
Publication of WO2009023164A2 publication Critical patent/WO2009023164A2/fr
Publication of WO2009023164A3 publication Critical patent/WO2009023164A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des compositions et des procédés d'induction de l'immunité des muqueuses induite par la cellule CD4+ T contre des antigènes sélectionnés, auxquels une réaction d'anti-corps ne confère pas de bénéfice clinique.
PCT/US2008/009584 2007-08-10 2008-08-11 Induction de l'immunité des muqueuses WO2009023164A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96437707P 2007-08-10 2007-08-10
US60/964,377 2007-08-10

Publications (2)

Publication Number Publication Date
WO2009023164A2 WO2009023164A2 (fr) 2009-02-19
WO2009023164A3 true WO2009023164A3 (fr) 2009-04-09

Family

ID=40202884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/009584 WO2009023164A2 (fr) 2007-08-10 2008-08-11 Induction de l'immunité des muqueuses

Country Status (1)

Country Link
WO (1) WO2009023164A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
AU2021252164A1 (en) 2020-04-09 2022-12-15 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032472A2 (fr) * 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Composition immunogene
WO2006122986A2 (fr) * 2005-05-20 2006-11-23 Institut Pasteur Utilisation de proteines se liant a la penicilline, ou de polynucleotides ou d'anticorps de celle-ci pour prevenir ou pour traiter des infections bacteriennes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006032472A2 (fr) * 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Composition immunogene
WO2006122986A2 (fr) * 2005-05-20 2006-11-23 Institut Pasteur Utilisation de proteines se liant a la penicilline, ou de polynucleotides ou d'anticorps de celle-ci pour prevenir ou pour traiter des infections bacteriennes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BASSET ALAN ET AL: "Antibody-independent, CD4(+) T-Cell-Dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins", INFECTION AND IMMUNITY, vol. 75, no. 11, November 2007 (2007-11-01), pages 5460 - 5464, XP002510337, ISSN: 0019-9567 *
BINA XIAOWEN R ET AL: "The Bla2 beta-lactamase from the live-vaccine strain of Francisella tularensis encodes a functional protein that is only active against penicillin-class beta-lactam antibiotics", ARCHIVES OF MICROBIOLOGY, vol. 186, no. 3, September 2006 (2006-09-01), pages 219 - 228, XP019419711, ISSN: 0302-8933 *
GREEN M ET AL: "Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 23, no. 20, 8 April 2005 (2005-04-08), pages 2680 - 2686, XP004789525, ISSN: 0264-410X *
OHWADA AKIHIKO ET AL: "DNA vaccination by mecA sequence evokes an antibacterial immune response against methicillin-resistant Staphylococcus aureus", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 44, no. 6, December 1999 (1999-12-01), pages 767 - 774, XP002510336, ISSN: 0305-7453 *
SENNA J P M ET AL: "Protective immune response against methicillin resistant Staphylococcus aureus in a murine model using a DNA vaccine approach", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 21, no. 19-20, 2 June 2003 (2003-06-02), pages 2661 - 2666, XP004424180, ISSN: 0264-410X *
TRZCINSKI KRZYSZTOF ET AL: "Protection against nasopharyngeal colonization by Streptococcus pneumoniae antigen-specific CD4(+) T cells", INFECTION AND IMMUNITY, vol. 76, no. 6, June 2008 (2008-06-01), pages 2678 - 2684, XP002510338, ISSN: 0019-9567 *

Also Published As

Publication number Publication date
WO2009023164A2 (fr) 2009-02-19

Similar Documents

Publication Publication Date Title
WO2007100908A3 (fr) Vecteurs anédoviraux chimériques
WO2009025888A3 (fr) Expression régulée d'antigène et/ou atténuation régulée pour accroître l'immunogénicité et/ou la sécurité de vaccins
WO2013054199A3 (fr) Antigènes de cmv et leurs utilisations
WO2008116078A8 (fr) Stimulation d'une réponse immunitaire par des lipides cationiques
WO2009026574A3 (fr) Compositions immunogènes et leurs utilisations
WO2007120673A3 (fr) Peptides wt1 immunogènes et leurs méthodes d'utilisation
WO2012027365A3 (fr) Formes pharmaceutiques multi-épitopes ciblées servant à l'induction d'une réponse immunitaire dirigée contre des antigènes
WO2011109833A3 (fr) Compositions de cellules dendritiques induites et utilisations associées
EP4324480A3 (fr) Anticorps anti-récepteur de transferrine et procédés d'utilisation
WO2008103947A3 (fr) Activation de cellules humaines présentant un antigène par l'intermédiaire de clec-6
EP1988919A4 (fr) Vaccin à base de levure destiné à induire une réponse immunitaire
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
EA201300585A1 (ru) Иммуномодулирующие олигонуклеотиды
WO2012064836A9 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
WO2008059252A3 (fr) Procédés et composition de récepteurs des lymphocytes t qui reconnaissent l'antigène 5t4
EP2652496A4 (fr) Antigènes de vaccin qui contrôlent l'immunité contre des épitopes conservés
IL211394B (en) Chimeric fusion proteins for inducing an immune response to p. gingivalis, preparations containing them and their uses
JO3437B1 (ar) أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها
WO2007144647A3 (fr) Compositions d'adjuvants innovantes
WO2008043000A3 (fr) Différenciation entre animaux vaccinés et animaux infectés (differentiate infected from vaccinated animals : diva) par ehrlicia canis
PH12013500616A1 (en) Antibody compositions and methods of use
IN2014CN03454A (fr)
WO2015031778A3 (fr) Compositions et méthodes pour le traitement ou la prévention de la tuberculose
WO2014151834A3 (fr) Procédés et compositions liés aux protéines de liaison à un antigène anti-ccr7

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08795193

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08795193

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载